Fibrin degradation products, abbreviated as FDP, refers to the formation of fibrinogen in the body after activating the body’s fibrinolytic enzymes, which can dissolve fibrinogen into fibrin degradation products. The first is primary fibrinolytic disease, which can be seen in patients with acute promyelocytic leukemia. Due to the presence of primary fibrinolysis, the patient is prone to bleeding symptoms, which can be treated with plasma transfusion and platelet transfusion. The second type of disease is secondary fibrinolytic disease. Common diseases include disseminated intravascular coagulation as well as pulmonary thromboembolism and deep vein thrombosis, all of which can have significantly high fibrin degradation products, as well as high fibrin degradation products after thrombolytic therapy.